WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

India’s pharma industry is going global. But can it catch up to China?

A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

Raccontata dabiopharmadive.comthehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo1 mesi fa

India’s pharma industry is going global. But can it catch up to China?

A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

originale
thehindubusinessline.com1 mesi fa

Domestic drugmakers make a play for the innovation league

Indian drugmakers are expanding globally through major acquisitions, signaling a shift towards innovation in complex pharmaceuticals.

Leggi questa versione → originale

Timeline cronologica

  1. venerdì 15 maggio 2026·biopharmadive.com

    India’s pharma industry is going global. But can it catch up to China?

    A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

  2. lunedì 18 maggio 2026·thehindubusinessline.com

    Domestic drugmakers make a play for the innovation league

    Indian drugmakers are expanding globally through major acquisitions, signaling a shift towards innovation in complex pharmaceuticals.